open access
The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value
open access
Abstract
Methods: Seventy eight patients (pts) with ACS were randomly divided into group A (39 pts) taking atorvastatin, and group NA (39 pts) not taking any statin for the following six weeks. C-reactive protein (CRP), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor alpha (TNFa) levels were measured on the first and the fifth days and six weeks after ACS.
Results: There was no significant CRP and IL-6 level decrease in group A (CRP - 62%; IL-6 - 73%) or group NA (CRP - 44%; IL-6 - 62%). There was also no significant change in TNFa levels. The MCP-1 level finally reached the level of significant difference (p < 0.04). Cardiovascular events (MACE) and the restenosis rates did not differ between the groups.
Conclusions: Low-dose atorvastatin does not have a significant influence on cooling down inflammation in ACS, and MCP-1 can be used as an early indicator of statin anti-inflammatory activity. Furthermore, it does not reduce MACE or restenosis rates despite its influence on MCP-1 levels.
Abstract
Methods: Seventy eight patients (pts) with ACS were randomly divided into group A (39 pts) taking atorvastatin, and group NA (39 pts) not taking any statin for the following six weeks. C-reactive protein (CRP), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor alpha (TNFa) levels were measured on the first and the fifth days and six weeks after ACS.
Results: There was no significant CRP and IL-6 level decrease in group A (CRP - 62%; IL-6 - 73%) or group NA (CRP - 44%; IL-6 - 62%). There was also no significant change in TNFa levels. The MCP-1 level finally reached the level of significant difference (p < 0.04). Cardiovascular events (MACE) and the restenosis rates did not differ between the groups.
Conclusions: Low-dose atorvastatin does not have a significant influence on cooling down inflammation in ACS, and MCP-1 can be used as an early indicator of statin anti-inflammatory activity. Furthermore, it does not reduce MACE or restenosis rates despite its influence on MCP-1 levels.
Keywords
atorvastatin; acute coronary syndrome; inflammation; CRP; IL-6; MCP-1; TNFa; restenosis
About this articleTitle
The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value
Journal
Issue
Pages
357-364
Published online
2008-05-21
Page views
847
Article views/downloads
1548
Bibliographic record
Cardiol J 2008;15(4):357-364.
Keywords
atorvastatin
acute coronary syndrome
inflammation
CRP
IL-6
MCP-1
TNFa
restenosis
Authors
Maciej Lewandowski
Zdzisława Kornacewicz-Jach
Barbara Millo
Joanna Zielonka
Małgorzata Czechowska
Robert Kaliszczak
Edyta Płońska
Jarosław Gorący
Jarosław Kaźmierczak
Marek Naruszewicz
